Rita Jain
Director/Board Member chez CELLDEX THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Rita I.
Jain is currently working as a Director at AnaptysBio, Inc., an Independent Director at Celldex Therapeutics, Inc., and a Member-Supervisory Board at both AM-Pharma Holding BV and AM-Pharma BV.
Previously, she held positions such as Chief Medical Officer, Executive Director & EVP at ChemoCentryx, Inc., Director at Provention Bio, Inc., Vice President-Pharmaceutical Development at Abbott Laboratories, Vice President-Health & Metabolic Development at AbbVie, Inc., Chief Medical Officer & Senior Vice President at Akebia Therapeutics, Inc., and Chief Medical Officer & Senior Vice President at Immunovant, Inc. She also served as an Assistant Professor at New York University School of Medicine and is a Member of North Shore University Hospital.
Dr. Jain completed her undergraduate degree at Long Island University and obtained her doctorate from Stony Brook University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ANAPTYSBIO, INC.
-.--% | 03/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Rita Jain
| Sociétés | Poste | Début |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Director/Board Member | 16/02/2023 |
| ANAPTYSBIO, INC. | Director/Board Member | 06/04/2023 |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Director/Board Member | 01/07/2020 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Director/Board Member | 01/01/2020 |
Anciens postes connus de Rita Jain
| Sociétés | Poste | Fin |
|---|---|---|
| PROVENTION BIO, INC. | Director/Board Member | 27/04/2023 |
| CHEMOCENTRYX, INC. | Chief Tech/Sci/R&D Officer | 20/10/2022 |
| IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
| AKEBIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17/06/2019 |
| ABBVIE INC. | Corporate Officer/Principal | 01/01/2012 |
Formation de Rita Jain
| Long Island University | Undergraduate Degree |
| Stony Brook University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| IMMUNOVANT, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Health Technology |
North Shore University Hospital
 North Shore University Hospital Hospital/Nursing ManagementHealth Services North Shore University Hospital Manhasset provided health care services. The company was headquartered in Manhasset, NY. | Health Services |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
